Main Outcomes and Measures
hemorrhage
ADVERSE EVENTS, HEMORRHAGE, METASTASIS
The primary end point was grade 4 hemorrhage or grade 5 adverse events in the first year. Secondary end points were locoregional progression–free (LRPF) interval, distant metastasis–free (DMF) interval, progression-free survival (PFS), overall survival (OS), and other adverse events. Long-term toxic effects and clinical outcomes were reported due to the limited follow-up in the initial report for this trial and the importance of long-term outcomes when combining bevacizumab with chemoradiation.